Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-RISES
NCT06745466Phase 4Recruiting
- Sponsor
- University of Delaware
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ganirelix (2 arms), sponsored by University of Delaware. Primary endpoints: Endothelium-dependent dilation, Negative affective response to daily stressors and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
ganirelix
Beyond the preview
Go deeper on NCT06745466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745466.